Amgen, an American multinational biopharmaceutical company, completed the acquisition of Horizon Therapeutics, a biopharmaceutical company focused on researching, developing, and commercializing medicines, for $27.8bn. "Today marks an exciting milestone as we welcome Horizon employees to Amgen and begin working together to serve even more patients around the world suffering from serious illnesses. We have strong momentum in our core business and the addition of Horizon will further position Amgen as a leader across a broader range of diseases," Robert A. Bradway, Amgen Chairman and CEO.